Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines

K. Kloudová, H. Hromádková, S. Partlová, T. Brtnický, L. Rob, J. Bartůňková, M. Hensler, MJ. Halaška, R. Špíšek, A. Fialová,

. 2016 ; 7 (29) : 46120-46126.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011153

Grantová podpora
NT14533 MZ0 CEP - Centrální evidence projektů

In order to select a suitable combination of cancer cell lines as an appropriate source of antigens for dendritic cell-based immunotherapy of ovarian cancer, we analyzed the expression level of 21 tumor associated antigens (BIRC5, CA125, CEA, DDX43, EPCAM, FOLR1, Her-2/neu, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MUC-1, NY-ESO-1, PRAME, p53, TPBG, TRT, WT1) in 4 established ovarian cancer cell lines and in primary tumor cells isolated from the high-grade serous epithelial ovarian cancer tissue. More than 90% of tumor samples expressed very high levels of CA125, FOLR1, EPCAM and MUC-1 and elevated levels of Her-2/neu, similarly to OVCAR-3 cell line. The combination of OV-90 and OVCAR-3 cell lines showed the highest overlap with patients' samples in the TAA expression profile.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011153
003      
CZ-PrNML
005      
20191115111017.0
007      
ta
008      
180404s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.10028 $2 doi
035    __
$a (PubMed)27323861
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kloudová, Kamila, $u Department of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic. Research Department, Sotio, Prague, Czech Republic. $d 1989- $7 xx0240740
245    10
$a Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines / $c K. Kloudová, H. Hromádková, S. Partlová, T. Brtnický, L. Rob, J. Bartůňková, M. Hensler, MJ. Halaška, R. Špíšek, A. Fialová,
520    9_
$a In order to select a suitable combination of cancer cell lines as an appropriate source of antigens for dendritic cell-based immunotherapy of ovarian cancer, we analyzed the expression level of 21 tumor associated antigens (BIRC5, CA125, CEA, DDX43, EPCAM, FOLR1, Her-2/neu, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MUC-1, NY-ESO-1, PRAME, p53, TPBG, TRT, WT1) in 4 established ovarian cancer cell lines and in primary tumor cells isolated from the high-grade serous epithelial ovarian cancer tissue. More than 90% of tumor samples expressed very high levels of CA125, FOLR1, EPCAM and MUC-1 and elevated levels of Her-2/neu, similarly to OVCAR-3 cell line. The combination of OV-90 and OVCAR-3 cell lines showed the highest overlap with patients' samples in the TAA expression profile.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antigeny nádorové $x analýza $7 D000951
650    _2
$a nádorové biomarkery $x analýza $7 D014408
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory glandulární a epitelové $x imunologie $7 D009375
650    _2
$a nádory vaječníků $x imunologie $7 D010051
650    12
$a transkriptom $7 D059467
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hromádková, Hana, $u Department of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic. $d 1982- $7 xx0118299
700    1_
$a Partlová, Simona $u Department of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic. Research Department, Sotio, Prague, Czech Republic. $7 _AN085265
700    1_
$a Brtnický, Tomáš, $u Department of Obstetrics and Gynaecology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic. $d 1981- $7 xx0194016
700    1_
$a Rob, Lukáš, $u Department of Obstetrics and Gynaecology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic. $d 1958- $7 xx0017807
700    1_
$a Bartůňková, Jiřina, $u Department of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic. $d 1958- $7 jn20000400093
700    1_
$a Hensler, Michal $u Research Department, Sotio, Prague, Czech Republic. $7 _AN044964
700    1_
$a Halaška, Michael J $u Department of Obstetrics and Gynaecology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Špíšek, Radek, $u Department of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic. Research Department, Sotio, Prague, Czech Republic. $d 1975- $7 nlk20030145288
700    1_
$a Fialová, Anna, $u Department of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic. Research Department, Sotio, Prague, Czech Republic. $d 1981- $7 stk2007393943
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 29 (2016), s. 46120-46126
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27323861 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20191115111256 $b ABA008
999    __
$a ok $b bmc $g 1288638 $s 1007965
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 29 $d 46120-46126 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
GRA    __
$a NT14533 $p MZ0
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace